TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia
Brief Summary: The purpose of this study is to confirm the efficacy and safety of duloxetine 60-120 mg once daily in comparison to placebo on symptom improvement in patients meeting criteria for fibromyalgia aged 18 and older. Patients will be randomized to duloxetine or placebo, however, all patients will receive duloxetine at some point in the study.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo | Arm Label: Pregabalin+Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin, Drug: Placebo | Arm Label: Duloxetine + Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine
D: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion of Clinical Pathways for the Implementation of Effective and Appropriate Care
Brief Summary: The purposes of this study are to determine whether clinical pathways: 1)improve the quality of the care provided to patients affected by stroke in terms of clinical outcomes, efficiency continuity of care and patients' satisfaction; 2) facilitate the use of evidence based medicine in clinical practice.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Clinical Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathways; Assigned to Arm(s): 1
B: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2
D: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion of Clinical Pathways for the Implementation of Effective and Appropriate Care
Brief Summary: The purposes of this study are to determine whether clinical pathways: 1)improve the quality of the care provided to patients affected by stroke in terms of clinical outcomes, efficiency continuity of care and patients' satisfaction; 2) facilitate the use of evidence based medicine in clinical practice.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Clinical Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathways; Assigned to Arm(s): 1
B: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention
C: Intervention Type: PROCEDURE; Name: structured therapeutic chain of stroke treatment; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II)
Brief Summary: The purpose of this study is to evaluate the effectiveness of the cognitive-behavioral treatment program CANDIS among n=450 patients with cannabis use disorders in a mulicenter randomized-controlled clinical trial (n=11 outpatient treatment centers).


Options:
A: Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavior Therapy | Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral treatment | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral treatment; Assigned to Arm(s): 1
C: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: control group; Type: OTHER; Interventions: Behavioral: Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): control group, intervention group
D: Arm Label: Cannabis users; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Cannabis no-users; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Cannabis no-users, Cannabis users

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study Comparing the Edwards Self-ExpandIng LifeStent Versus Angioplasty-alone In LEsions INvolving The SFA and/or Proximal Popliteal Arter
Brief Summary: The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral artery (SFA) disease by reducing the re-intervention rate as compared to percutaneous transluminal angioplasty (PTA) alone


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Zilver® PTX™ Drug Eluting Vascular Stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty | Intervention Type: DEVICE; Name: Zilver® PTX™ Drug Eluting Vascular Stent; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Angioplasty; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Percutaneous Transluminal Angioplasty | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: LifeStent NT™ Self-Expanding Peripheral Stent | Intervention Type: OTHER; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: LifeStent NT™ Self-Expanding Peripheral Stent; Assigned to Arm(s): 2
C: Arm Label: Pantheris Treatment Arm; Type: EXPERIMENTAL; Interventions: Device: Pantheris System | Intervention Type: DEVICE; Name: Pantheris System; Assigned to Arm(s): Pantheris Treatment Arm
D: Arm Label: REA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote endarterectomy of the superficial femoral artery | Arm Label: Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Suprageniculate femoropopliteal bypass | Intervention Type: PROCEDURE; Name: Remote endarterectomy of the superficial femoral artery; Assigned to Arm(s): REA | Intervention Type: PROCEDURE; Name: Suprageniculate femoropopliteal bypass; Assigned to Arm(s): Bypass

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for Treatment of Incomplete Abortion
Brief Summary: This study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: new crosslinked hyaluronan gel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: new crosslinked hyaluronan gel; Assigned to Arm(s): Treatment
B: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
C: Arm Label: Arm A : Operative hysteroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Hysteroscopy | Arm Label: Arm B : Aspirative curettage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Curettage | Intervention Type: PROCEDURE; Name: Hysteroscopy; Assigned to Arm(s): Arm A : Operative hysteroscopy | Intervention Type: PROCEDURE; Name: Curettage; Assigned to Arm(s): Arm B : Aspirative curettage
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for Treatment of Incomplete Abortion
Brief Summary: This study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
B: Arm Label: misoprostol plus mifepristone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol, Drug: Mifepristone | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol, misoprostol plus mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): misoprostol plus mifepristone
C: Arm Label: Misoprostol 800 micrograms intravaginally; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: expectant managment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): Misoprostol 800 micrograms intravaginally
D: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for Treatment of Incomplete Abortion
Brief Summary: This study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
B: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
C: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Misoprostol for Treatment of Incomplete Abortion
Brief Summary: This study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.


Options:
A: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
C: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis
Brief Summary: To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity rheumatoid arthritis


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: TNF-blocking drug; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Adalimumab, Drug: Certolizumab Pegol, Drug: Infliximab, Drug: Golimumab | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rituximab | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): TNF-blocking drug
C: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis
Brief Summary: To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity rheumatoid arthritis


Options:
A: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)
B: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
D: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis
Brief Summary: To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity rheumatoid arthritis


Options:
A: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Open Label Infliximab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Infliximab + methotrexate (MTX) | Intervention Type: BIOLOGICAL; Name: Infliximab + methotrexate (MTX); Assigned to Arm(s): Open Label Infliximab + Methotrexate
C: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Arm Label: Infliximab + MTX (DB); Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab (INF) + MTX, DB | Arm Label: Placebo + MTX (DB); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (PLA) + MTX, DB | Arm Label: Placebo + MTX switched to abatacept + MTX (DB); Type: EXPERIMENTAL; Interventions: Drug: PLA + MTX switched to ABA+ MTX, DB | Arm Label: Abatacept (open-label); Type: EXPERIMENTAL; Interventions: Drug: ABA, open-label (OL) | Intervention Type: DRUG; Name: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB); Assigned to Arm(s): Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) | Intervention Type: DRUG; Name: Infliximab (INF) + MTX, DB; Assigned to Arm(s): Infliximab + MTX (DB) | Intervention Type: DRUG; Name: Placebo (PLA) + MTX, DB; Assigned to Arm(s): Placebo + MTX (DB) | Intervention Type: DRUG; Name: PLA + MTX switched to ABA+ MTX, DB; Assigned to Arm(s): Placebo + MTX switched to abatacept + MTX (DB) | Intervention Type: DRUG; Name: ABA, open-label (OL); Assigned to Arm(s): Abatacept (open-label)

Answer: C